Ozmosi | 18F-LNC1017 Drug Profile
Drug Profile
Using advanced filters...
Advanced Search [+]

18F-LNC1017

Alternative Names: 18F-LNC1017, 18FLNC1017, 18F LNC1017, LNC1017
Clinical Status: Active
Latest Update: 2026-08-21
Latest Update Note: Clinical Trial Update

Product Description

(Sourced from: https://www1.hkexnews.hk/app/sehk/2026/108638/documents/sehk26061202231.pdf)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Unknown

Route of Administration: N/A

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Company: Yantai Lannacheng Biotechnology Co., Ltd.
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 0: Small Cell Lung Cancer

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

Recent News Events

Date

Type

Title